ScreenerHero

RGNX REGENXBIO Inc.

NAS · US · Healthcare · Biotechnology · regenxbio.com
7.595USD+1.95%Mkt Cap: 501.37M $P/E: —

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Techn…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap501.37M USD
Enterprise Value636.74M USD
Revenue (TTM)174.48M USD
Gross Profit150.14M USD
Net Income (TTM)-193.88M USD
Revenue/Share3.34 USD
Last Price7.595 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees371
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.50
PEG—
EV/EBITDA-4.28
EV/Revenue3.65
P/S2.82
P/B5.62
EPS (TTM)-3.63
EPS (Forward)-2.98
52W Range
5.45520% of range16.19
52W High16.19 USD
52W Low5.455 USD
Profitability
Gross Margin88.09%
Oper. Margin27.09%
EBITDA Margin-85.27%
Profit Margin-113.75%
ROE-188.72%
ROA-42.80%
Growth
Revenue Growth405.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-123.96M USD
CapEx (TTM)2.41M USD
FCF Margin-105.61%
FCF Yield-36.75%
Net Debt144.94M USD
Net Debt/EBITDA-0.97
Balance Sheet
Debt/Equity0.72
Current Ratio2.86
Quick Ratio2.70
Book Value/Sh1.32 USD
Cash/Share1.60 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)23.58 USD
Upside (mean)+210.5%
Target Range10.00 USD – 50.00 USD
10.00+210.5% to mean50.00
# Analysts12
Ownership
Shares Out.66.01M
Float57.23M
Insiders6.55%
Institutions65.26%
Short Interest
Short Ratio6.0d
Short % Float12.71%
Short % Out.12.01%
Shares Short7.93M
Short (prev mo.)8.20M
Technical
SMA 509.234 (-17.8%)
SMA 2009.847 (-22.9%)
Beta1.13
S&P 52W Chg16.45%
Avg Vol (30d)1.42M
Avg Vol (10d)1.54M
Technical Indicators
RSI (14)40.3
MACD-0.5666
MACD Signal-0.6276
MACD Hist.+0.0610
BB Upper9.068 USD
BB Middle7.929 USD
BB Lower6.790 USD
BB Width28.74%
ATR (14)0.5668 USD
Vol Ratio (20d)0.72x